ASLAN Pharmaceuticals Ltd - ADR

NASDAQ:ASLN   3:59:59 PM EDT
1.40
-0.07 (-4.76%)
Products

Aslan Pharmaceuticals Announces Positive Data Conclusively Establishing Proof Of Concept For Aslan004 In Atopic Dermatitis

Published: 09/27/2021 10:07 GMT
ASLAN Pharmaceuticals Ltd - ADR (ASLN) - Aslan Pharmaceuticals Announces Positive Data Conclusively Establishing Proof of Concept for Aslan004 in Atopic Dermatitis.
Aslan Pharmaceuticals Ltd - Topline Data From Multiple-ascending-dose Study Supports a Potentially Differentiated Safety and Efficacy Profile.
Aslan Pharmaceuticals Ltd - Well-tolerated With No Cases of Conjunctivitis in Expansion Cohort.
Aslan Pharmaceuticals Ltd - on Track to Enroll First Patient in Global Phase 2b Study in 4q 21.